Table 3

Returns to hepatitis C treatment of 100 persons in 2017 for the period 2017–2050 by sex and age

(1) Costs(2) SavingsNet costAvertedCost per
TotalHepatitis C treatmentCirrhosis and liver cancer treatmentTotal(1) minus
(2)
InfectionDeathInfection avertedDeath averted
Male
 20–291 039 000872 874190 6501 063 524−24 52417.01.67−1440−14 680
 30–391 039 000856 106299 9941 156 100−117 10017.73.48−6609−33 695
 40–491 039 000851 311501 4891 352 800−313 80015.87.82−19 866−40 136
 50–591 039 000836 151331 9471 168 098−129 09813.48.90−9606−14 500
 60–691 039 000778 178207 695985 87453 12611.111.2147914737
 70+1 039 000606 89356 394663 287375 7138.18.0946 30346 441
 20+1 039 000812 871311 7021 124 573−85 57313.68.14−6278−10,512
Female
 20–291 039 000844 36318 545862 908176 09219.10.239216764 891
 30–391 039 000829 79539 472869 267169 73320.00.428492399 695
 40–491 039 000818 50395 966914 469124 53121.01.175944106 531
 50–591 039 000824 358156 745981 10357 89719.22.38302224 323
 60–691 039 000802 704207 7611 010 46428 53616.93.9016857326
 70+1 039 000634 720120 913755 633283 36712.03.2623 61486 936
 20+1 039 000758 304141 486900 666138 33416.52.76836750 177
  • Table shows costs and consequences of placing an additional 100 individuals on treatment, evaluated around the status quo scenario. Costs of testing are subsumed under treatment costs, and it is assumed that 12 individuals are tested for each person progressing to treatment. All totals are through 2050, and we used the 2016 year-average exchange rate29 to convert Korean won to US dollars (KRW 1160) and a discount rate of 3%.30